Observational study shows improved survival with the Ross procedure in patients with infective endocarditis, indicating its potential advantages over valve replacement.
OBJECTIVES Infective endocarditis (IE) is associated with high morbidity and mortality; nearly 40% present with isolated aortic valve (AV) endocarditis. No detailed guidelines on surgical strategies are currently available particularly for younger patients. The aim of this study was to compare mid-term results of conventional valve(AVR) and root replacement and the Ross procedure in patients < 60 years. METHODS Between 1997 and 2023, 176patients >18 and <60 years underwent surgery for AV IE. Patients with AV repair (n = 44) were excluded; the remaining 132 (male 82%; mean age 46 ± 11 years) underwent a Ross procedure(n = 32),mechanical AVR(n = 28), biological AVR(n = 72). Median and mean follow-up were 6.4[IQR 2.1–12.9]years and 7.9 ± 6.6 years(1041patient-years). RESULTS Twenty-seven patients(20%; Ross n = 1, biological AVR n = 20, mechanical AVR n = 6; p = 0.033) required permanent pacemaker implantation , 15patients had recurrent endocarditis(11%; Ross n = 1, biological AVR n = 11, mechanical AVR n = 3; p = 0.028). Survival was 78% at 15 years (Ross 92%; biological AVR 72%; mechanical AVR 70%; p = 0.176). At 15 years, it was 79% after native valve and 73% after prosthetic valve IE (p = 0.622), and 66% after biological AVR and 93% after root replacement (p = 0.05). At 15 years, freedom from AV reoperation was 72%(Ross 73%; biological stented AVR 58%; biological stentless root replacement 76%; mechanical AVR 82%; p = 0.453). CONCLUSIONS Long-term survival was good after the Ross procedure and stentless biological valves but was best after the Ross procedure with the lowest valve-related complications. Reoperation was non-negligible but similar between the Ross procedure and stentless biological root. Abscess exclusion with a patch and subsequent valve replacement was associated with inferior results. The Ross procedure offers the best potential for true long-term durability. In patients >50 years, stentless biological root replacement may be an alternative.
No takes yet. Share an insight, caveat, or question.
Abeln et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: